Satien company delays the launch of Ryjunea, a product to slow the progression of myopia in children, in Germany.

On July 23, Santen Pharmaceutical announced that its product Ryjunea, used to delay the progression of myopia in children, has officially launched in Germany. Germany is the first market to sell the product after it received approval from the European Commission on June 2. The product will gradually launch in other European countries.